Fludarabine exposure predicts outcome after CD19 CAR T-cell therapy in children and young adults with acute leukemia

The addition of fludarabine to cyclophosphamide as a lymphodepleting regimen prior to CD19 chimeric antigen receptor (CAR) T-cell therapy significantly improved outcomes in patients with relapsed/refractory (r/r) B-cell acute lymphoblastic leukemia (B-ALL). Fludarabine exposure, previously shown to...

Descripción completa

Detalles Bibliográficos
Autores principales: Dekker, Linde, Calkoen, Friso G., Jiang, Yilin, Blok, Hilly, Veldkamp, Saskia R., De Koning, Coco, Spoon, Maike, Admiraal, Rick, Hoogerbrugge, Peter, Vormoor, Britta, Vormoor, H. Josef, Visscher, Henk, Bierings, Marc, Van Der Vlugt, Marieke, Van Tinteren, Harm, Nijstad, A. Laura, Huitema, Alwin D. R., Van Der Elst, Kim C. M., Pieters, Rob, Lindemans, Caroline A., Nierkens, Stefan
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Society of Hematology 2022
Materias:
Immunobiology and Immunotherapy
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9006280/
https://www.ncbi.nlm.nih.gov/pubmed/35134115
http://dx.doi.org/10.1182/bloodadvances.2021006700

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9006280/
https://www.ncbi.nlm.nih.gov/pubmed/35134115
http://dx.doi.org/10.1182/bloodadvances.2021006700

Ejemplares similares